STP Links
Resources
Contact Information
  •   11190 Sunrise Valley Dr., Suite 300, Reston, VA, 20191
  •   stp@toxpath.org
  •   703-438-7508
open

Best Practices & Points to Consider Papers

Home / Publications / STP Publications / Best Practices & Points to Consider Papers

  • Aeffner F, Bolon B, Boyle MH, et al. (2025).
    Scientific and Regulatory Policy Committee Points to Consider*: Sample Selection, Assay Design, Data Generation and Interpretation, and Reporting Practices for Chromogenic Immunohistochemical (IHC) Assays in Nonclinical Drug Development. Toxicologic Pathology, 54(3):233-266. doi:10.1177/01926233251393154

  • Colman K, Funk KA, Boyle M, et al. (2025).
    Scientific and Regulatory Policy Committee Points to Consider* for Determining and Reporting Cause of Death/Moribundity in Non-Rodent Species in Toxicity Studies.Toxicologic Pathology, 53(5):501-510. doi:10.1177/01926233251321781

  • Hahn K, Amberg B, Monné Rodriguez JM, et al. (2025).
    Points to Consider From the ESTP Pathology 2.0 Working Group: Overview on Spatial Omics Technologies Supporting Drug Discovery and Development. Toxicologic Pathology, 53(1), 107-129. doi:10.1177/01926233241311258

  • McDorman KS, Bennet BM, Colman K, et al. (2024).
    Scientific and Regulatory Policy Committee Points to Consider: Review of the United States Food and Drug Administration (FDA) Guidance on Pathology Peer Review in Nonclinical Toxicology Studies.     Toxicologic Pathology, 52(2-3):138-148. doi:10.1177/01926233241248654

  • Bennet BM, Pardo ID, Assaf BT, et al. (2023).
    Scientific and Regulatory Policy Committee Technical Review: Biology and Pathology of Ganglia in Animal Species Used for Nonclinical Safety Testing.     Toxicologic Pathology, 51(5):278-305. doi:10.1177/01926233231213851

  • Bolon B, Francke S, Caverly Rae JM, et al. (2022).
    Scientific and Regulatory Policy Committee Best Practices: Recommended ("Best") Practices for Informed (Non-blinded) Versus Masked (Blinded) Microscopic Evaluation in Animal Toxicity Studies. Toxicologic Pathology, 50(8):930-941. doi:10.1177/01926233221135563

  • Siska W, Schultze AE, Ennulat D, et al. (2022).
    Scientific and Regulatory Policy Committee Points to Consider: Integration of Clinical Pathology Data With Anatomic Pathology Data in Nonclinical Toxicology Studies. Toxicologic Pathology, 50(6):808-826. doi:10.1177/01926233221108887

  • O'Brien MT, Schuh JCL, Wancket LM, et al. (2022).
    Scientific and Regulatory Policy Committee Points to Consider for Medical Device Implant Site Evaluation in Nonclinical Studies. Toxicologic Pathology, 50(4):512-530. doi:10.1177/01926233221103202

  • Forest T, Aeffner F, Bangari DS, et al. (2022).
    Scientific and Regulatory Policy Committee Brief Communication: 2019 Survey on Use of Digital Histopathology Systems in Nonclinical Toxicology Studies. Toxicologic Pathology, 50(3):397-401. doi:10.1177/01926233221084621

  • Harbison CE, Aulbach AD, Bennet BM, et al. (2022).
    Scientific and Regulatory Policy Committee Points to Consider: Biological Sample Retention From Nonclinical Toxicity Studies.
    Toxicologic Pathology, 50(2):252-265. doi:10.1177/01926233211049156

  • Booler HS, Lejeune T, Sorden S, et al. (2022).
    Scientific and Regulatory Policy Committee Points to Consider: Fixation, Trimming, and Sectioning of Nonrodent Eyes and Ocular Tissues for Examination in Ocular and General Toxicity Studies. Toxicologic Pathology, 50(2):235-251. doi:10.1177/01926233211047562

  • Hutt JA, Assaf BT, Bolon B, et al. (2022).
    Scientific and Regulatory Policy Committee Points to Consider: Nonclinical Research and Development of In Vivo Gene Therapy Products, Emphasizing Adeno-Associated Virus Vectors.     Toxicologic Pathology, 50(1):118-146. doi:10.1177/01926233211041962

  • Vidal JD, Colman K, Bhaskaran M, et al. (2021).
    Scientific and Regulatory Policy Committee Best Practices: Documentation of Sexual Maturity by Microscopic Evaluation in Nonclinical Safety Studies. Toxicologic Pathology, 49(5):977-989. doi:10.1177/0192623321990631

  • Sellers, R. S., Nelson, K., Bennet, B., Wolf, J., Tripathi, N., Chamanza, R., Lepage, M. P., Adkins, K., Laurent, S., & Troth, S. P. (2020).
    Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists. Toxicologic Pathology, 48(2), 257-276. doi:10.1177/019262331987508

  • Hukkanen, R. R., Dybdal, N., Tripathi, N., Turner, P. V., & Troth, S. P. (2019).
    Scientific and Regulatory Policy Committee Points to Consider*: The Toxicologic Pathologist’s Role in the 3Rs. Toxicologic Pathology, 47(7), 789-798. doi:10.1177/0192623319859261

  • Keirstead, N. D., Janovitz, E. B., Meehan, J. T., LeRoy, B. E., Megill, J. R., Peterson, R. A., Masson, R. G., & Marxfeld, H. A. (2019).
    Scientific and Regulatory Policy Committee Points to Consider*: Review of Scientific and Regulatory Policy Committee Points to Consider: Review of Current Practices for Ultrastructural Pathology Evaluations in Support of Nonclinical Toxicology Studies
    Toxicologic Pathology, 47(4), 461-468. doi:10.1177/0192623319835170

  • Irizarry Rovira, A. R., Bennet, B. M., Bolon, B., Braendli-Baiocco, A., Chandra, S., Fleurance, R., Garman, R., Hutto, D., Lane, J., Romeike, A., Sargeant, A., & Zimmerman, B. (2018).
    Scientific and Regulatory Policy Committee Points to Consider: Histopathologic Evaluation in Safety Assessment Studies for PEGylated Pharmaceutical Products. 
    Toxicologic Pathology, 46(6), 616-635. doi:10.1177/0192623318791801

  • Troth, S. P., Everds, N. E., Siska, W., Knight, B., Lamb, M., & Hutt, J. (2018).
    Scientific and Regulatory Policy Committee Points to Consider: Data Visualization for Clinical and Anatomic Pathologists. Toxicologic Pathology, 46(5), 476-487. doi:10.1177/0192623318778733

  • Bolon, B., Krinke, G., Butt, M., Rao, D. B., Pardo, I. D., Jortner, B. S., Garman, R. H., Jensen, K., Andrews-Jones, L., Morrison, J. P., Sharma, A. K., & Thibodeau, M. S. (2018).
    STP Position Paper: Recommended Best Practices for Sampling, Processing, and Analysis of the Peripheral Nervous System (Nerves and Somatic and Autonomic Ganglia) during Nonclinical Toxicity Studies. Toxicologic Pathology, 46(4):372-402. 10.1177/0192623318772484

  • Schafer, K. A., Eighmy, J., Fikes, J. D., Halpern, W. G., Hukkanen, R. R., Long, G. G., Meseck, E. K., Patrick, D. J., Thibodeau, M. S., Wood, C. E., & Francke, S. (2018).
    Use of Severity Grades to Characterize Histopathologic Changes. Toxicologic Pathology, 46(3), 256-265. doi:10.1177/0192623318761348

  • Halpern, W. G., Ameri, M., Bowman, C. J., Elwell, M. R., Mirsky, M. L., Oliver, J., Regan, K. S., Remick, A. K., Sutherland, V. L., Thompson, K. E., Tremblay, C., Yoshida, M., & Tomlinson, L. (2016).
    Scientific and Regulatory Policy Committee Points to Consider Review: Inclusion of Reproductive and Pathology End Points for Assessment of Reproductive and Developmental Toxicity in Pharmaceutical Drug Development. Toxicologic Pathology. , 44(6), 789-809. doi:10.1177/0192623316650052

  • Elmore SA, Dixon D, Hailey JR, et al. (2016).
    Recommendations from the INHAND Apoptosis/Necrosis Working Group.
    Toxicologic Pathology, 44(2):173-188. doi:10.1177/0192623315625859

  • Kerlin, R., Bolon, B., Burkhardt, J., Francke, S., Greaves, P., Meador, V., & Popp, J. (2016).
    Scientific and Regulatory Policy Committee: Recommended (“Best”) Practices for Determining, Communicating, and Using Adverse Effect Data from Nonclinical Studies. Toxicologic Pathology, 44(2), 147-162. doi:10.1177/0192623315623265

  • Tomlinson, L., Ramaiah, L., Tripathi, N. K., Barlow, V. G., Vitsky, A., Poitout-Belissent, F. M., Bounous, D. L., & Ennulat, D. (2016).
    STP Best Practices for Evaluating Clinical Pathology in Pharmaceutical Recovery Studies. Toxicologic Pathology, 44(2), 163-172. doi:10.1177/0192623315624165

  • Keane, K. A., Parker, G. A., Regan, K. S., Picut, C., Dixon, D., Creasy, D., Giri, D., & Hukkanen, R. R. (2015).
    Scientific and Regulatory Policy Committee (SRPC) Points to Consider: Histopathology Evaluation of the Pubertal Development and Thyroid Function Assay (OPPTS 890.1450, OPPTS 890.1500) in Rats to Screen for Endocrine Disruptors. 
    Toxicologic Pathology, 43(8), 1047-1063. doi:10.1177/0192623315579943

  • Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., Zabka, T. S., & Frazier, K. S. (2015).
    Scientific and Regulatory Policy Committee Points-to-consider Paper*: Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part 2. Antisense Oligonucleotides. Toxicologic Pathology, 43(7), 935-944. doi:10.1177/0192623315570341

  • Fikes, J. D., Patrick, D. J., Francke, S., Frazier, K. S., Reindel, J. F., Romeike, A., Spaet, R. H., Tomlinson, L., Schafer, K. A. (2015).
    Scientific and Regulatory Policy Committee Review: Review of the Organisation for Economic Co-operation and Development (OECD) Guidance on the GLP Requirements for Peer Review of Histopathology. Toxicologic Pathology, 43(7), 907-914. doi:10.1177/0192623315596382

  • Frazier, K. S., Engelhardt, J. A., Fant, P., Guionaud, S., Henry, S. P., Leach, M. W., Louden, C., Scicchitano, M. S., Weaver, J. L., & Zabka, T. S. (2015).
    Scientific and Regulatory Policy Committee Points-to-consider Paper*:Drug-induced Vascular Injury Associated with Nonsmall Molecule Therapeutics in Preclinical Development: Part I. Biotherapeutics. Toxicologic Pathology, 43(7), 915-934. doi:10.1177/0192623315570340

  • Wood CE, Hukkanen RR, Sura R, et al. (2015).
    Scientific and Regulatory Policy Committee (SRPC) Review: Interpretation and Use of Cell Proliferation Data in Cancer Risk Assessment. Toxicologic Pathology, 43(6):760-775. doi:10.1177/0192623315576005

  • Nikula, K. J., McCartney, J. E., McGovern, T., Miller, G. K., Odin, M. Pino, M. V., & Reed, M. D. (2014).
    STP Position Paper: Interpreting the Significance of Increased Alveolar Macrophages in Rodents Following Inhalation of Pharmaceutical Materials. Toxicologic Pathology, 42(3), 472-486. doi:10.1177/0192623313507003

  • Tomlinson, L., Boone, L. I., Ramaiah, L., Penraat, K. A., von Beust, B. R., Ameri, M., Poitout‐Belissent, F. M., Weingand, K., Workman, H. C., Aulbach, A. D., Meyer, D. J., Brown, D. E., MacNeill, A. L., Bolliger, A. P., & Bounous, D. L. (2013).
    Best Practices for Veterinary Toxicologic Clinical Pathology, with Emphasis on the Pharmaceutical and Biotechnology Industries. Veterinary Clinical Pathology, 42(3), 252-269. doi:10.1111/vcp.12059

  • Andersson, H., Rehm, S., Stanislaus, D., & Wood, C. E. (2013).
    Scientific and Regulatory Policy Committee (SRPC) Paper: Assessment of Circulating Hormones in Nonclinical Toxicity Studies III. Female Reproductive Hormones. Toxicologic Pathology, 41(6), 921-934. doi:10.1177/0192623312466959

  • Bolon, B., Garman, R. H., Pardo, I. D., Jensen, K., Sills, R. C., Roulois, A., Radovsky, A., Bradley, A., Andrews-Jones, L., Butt, M., & Gumprecht, L. (2013).
    STP Position Paper: Recommended Practices for Sampling and Processing the Nervous System (Brain, Spinal Cord, Nerve, and Eye) during Nonclinical General Toxicity Studies. Toxicologic Pathology, 41(7), 1028-1048. doi:10.1177/0192623312474865

  • Everds, N. E., Snyder, P. W., Bailey, K. L., Bolon, B., Creasy, D. M., Foley, G. L., Rosol, T. J., & Sellers, T. (2013).
    Interpreting Stress Responses during Routine Toxicity Studies: A Review of the Biology, Impact, and Assessment. Toxicologic Pathology, 41(4), 560-614. doi:10.1177/0192623312466452

  • Morgan, S. J., Elangbam, C. S., Berens, S., Janovitz, E., Vitsky, A., Zabka, T., & Conour L. (2013).
    Use of Animal Models of Human Disease for Nonclinical Safety Assessment of Novel Pharmaceuticals. Toxicologic Pathology, 41(3), 508-518. doi:10.1177/0192623312457273

  • Perry, R., Farris, G., Bienvenu, J., Dean, Jr, C., Foley, G., Mahrt, C., & Short, B. (2013).
    Society of Toxicologic Pathology Position Paper on Best Practices on Recovery Studies: The Role of the Anatomic Pathologist. Toxicologic Pathology, 41(8), 1159-1169. doi:10.1177/0192623313481513

  • Long, R. E., Smith, A., Machotka, S. V., Chlipala, E., Cann, J., Knight, B., Kawano, Y., Ellin, J., & Lowe, A. (2013).
    Scientific and Regulatory Policy Committee (SRPC) Paper: Validation of Digital Pathology Systems in the Regulated Nonclinical Environment. Toxicologic Pathology, 41(1), 115-124. doi:10.1177/0192623312451162

  • Chapin, R. E., & Creasy, D. M. (2012).\
    Assessment of Circulating Hormones in Regulatory Toxicity Studies II. Male Reproductive Hormones. Toxicologic Pathology, 40(7), 1063-1078. doi:10.1177/0192623312443321

  • Stanislaus, D., Andersson, H., Chapin, R., Creasy, D., Ferguson, D., Gilbert, M., Rosol, T. J., Boyce, R. W., & Wood, C. E. (2012).
    Society of Toxicologic Pathology Position Paper: Review Series: Assessment of Circulating Hormones in Nonclinical Toxicity Studies: General Concepts and Considerations. Toxicologic Pathology, 40(6), 943-950. doi:10.1177/0192623312444622

  • Burkhardt, J. E., Pandher, K., Solter, P.F., Troth, S. P., Boyce, R. W., Zabka, T. S., & Ennulat, D. (2011).
    Recommendations for the Evaluation of Pathology Data in Nonclinical Safety Biomarker Qualification Studies. Toxicologic Pathology, 39(7), 1129-1137. doi:10.1177/0192623311422082

  • Best practice paper from ASVCP/STP Clinical Pathology in Carcinogenicity Studies Working Group
    Young, J. K., Hall, R. L., O’Brien, P., Strauss, V., & Vahle, J. L. (2011).
    Best Practices for Clinical Pathology Testing in Carcinogenicity Studies. Toxicologic Pathology, 39(2), 429-434. doi:10.1177/0192623310396512

  • Best practice paper from Bone Marrow Working Group of ASVCP/STP
    Reagan, W. J., Irizarry-Rovira, A., Poitout-Belissent, F., Bolliger, A. P., Ramaiah, S. K., Travlos, G., Walker, D., Bounous, D., & Walter, G. (2011).
    Best Practices for Evaluation of Bone Marrow in Nonclinical Toxicity Studies. Toxicologic Pathology, 39(2), 435-448. doi:10.1177/0192623310396907

  • Morton, D., Sellers, R. S., Barale-Thomas, E., Bolon, B., George, C., Hardisty, J. F., Irizarry, A., McKay, J. S., Odin, M., & Teranishi, M.F. (2010).
    Recommendations for Pathology Peer Review. Toxicologic Pathology, 38(7), 1118-1127. doi:10.1177/0192623310383991

  • International Federation of Societies of Toxicologic Pathologists (IFSTP)
    Bolon, B., Barale-Thomas, E., Bradley, A., Ettlin, R. A., Franchi, C. A. S., George, C., Giusti, A. M., Hall, R., Jacobsen, M., Konishi, Y., Ledieu, D., Morton, D., Park, J. H., Scudamore, C. L., Tsuda, H., Vijayasarathi, S. K., & Wijnands, M. V. W. (2010).
    International Recommendations for Training Future Toxicologic Pathologists Participating in Regulatory-type, Nonclinical Toxicity Studies. Toxicologic Pathology, 38(6), 984-992. doi:10.1177/0192623310378137

  • Vahle JL, Finch GL, Heidel SM, et al. (2010).
    Carcinogenicity Assessments of Biotechnology-Derived Pharmaceuticals: A Review of Approved Molecules and Best Practice Recommendations. Toxicologic Pathology, 38(4):522-553. doi:10.1177/0192623310368984

  • Keenan, C., Elmore, S., Francke-Carroll, S., Kemp, R., Kerlin, R., Peddada, S., Pletcher, J., Rinke, M., Schmidt, S. P., Taylor, I., & Wolf, D. C. (2009).
    Best Practices for Use of Historical Control Data of Proliferative Rodent Lesions. 
    Toxicologic Pathology, 37(5), 679-693. doi:10.1177/0192623309336154

  • Elmore, S., & Peddada, S., (2009).
    Points to Consider on the Statistical Analysis of Rodent Cancer Bioassay Data When Incorporating Historical Control Data. Toxicologic Pathology, 37(5), 672-676. doi:10.1177/0192623309339606
  • Vidal JD, Mirabile RC, Thomas HC. (2008).
    Evaluation of the Cynomolgus Monkey Stomach: Recommendations for Standard Sampling Procedures in Nonclinical Safety Studies. Toxicologic Pathology, 36(2):250-255. doi:10.1177/0192623307312700

  • Michael, B., Yano, B., Sellers, R. S., Perry, R., Morton, D., Roome, N., Johnson, J. K., & Schafer, K. (2007).
    Evaluation of Organ Weights for Rodent and Non-Rodent Toxicity Studies: A Review of Regulatory Guidelines and a Survey of Current Practices. Toxicologic Pathology, 35(5), 742-750. doi:10.1177/01926230701595292

  • Tuomari, D. L., Kemp, R. K., Sellers, R., Yarrington, J. T., Geoly, F. J., Fouillet, X. L. M., Dybdal, N., & Perry, R. (2007).
    Society of Toxicologic Pathology Position Paper on Pathology Image Data: Compliance with 21 CFR Parts 58 and 11. Toxicologic Pathology, 35(3), 450-455. doi:10.1080/01926230701284509

  • Sellers, R. S., Morton, D., Michael, B., Roome, N., Johnson, J. K., Yano, B. Y., Perry, R., & Schafer, K. (2007).
    Society of Toxicologic Pathology Position Paper: Organ Weight Recommendations for Toxicology Studies. Toxicologic Pathology, 35(5), 751-755. doi:10.1080/01926230701595300

  • Morton, D., Kemp, R. K., Francke-Carroll, S., Jensen*, K., McCartney, J., Monticello, T. M., Perry, R., Pulido, O., Roome, N., Schafer, K., Sellers, R., & Snyder, P. W. (2006).
    Best Practices for Reporting Pathology Interpretations within GLP Toxicology Studies. Toxicologic Pathology, 34(6), 1118-1127. doi:10.1080/01926230601034624

  • Ad Hoc Working Group of the STP Scientific and Regulatory Policy Committee
    Bolon, B., Garman, R., Jensen, K., Krinke, G., & Stuart, B. (2006).
    STP Position Paper: A ‘Best Practices’ Approach to Neuropathologic Assessment in Developmental Neurotoxicity Testing—for Today. 
    Toxicologic Pathology, 34(3), 296-313. doi:10.1080/01926230600713269

  • Hard GC, Seely JC. (2005).
    Recommendations for the Interpretation of Renal Tubule Proliferative Lesions Occurring in Rat Kidneys with Advanced Chronic Progressive Nephropathy (CPN). Toxicologic Pathology, 33(6):641-649. 10.1080/01926230500299716

  • STP Immunotoxicology Working Group
    Haley, P., Perry, R., Ennulat, D., Frame, S., Johnson, C., Lapointe, J. M., Nyska, A., Snyder, P. W., Walker, D. & Walter, G. (2005).
    STP Position Paper: Best Practice Guideline for the Routine Pathology Evaluation of the Immune System. Toxicologic Pathology, 33(3), 404-407. doi:10.1080/01926230590934304

  • Regan KS, Cline JM, Creasy D, et al. (2005).
    STP Position Paper: Ovarian Follicular Counting in the Assessment of Rodent Reproductive Toxicity
    Toxicologic Pathology, 33(3):409-412. doi: 10.1080/01926230490515355

  • Regulatory Affairs Committee of the American Society for Veterinary Clinical Pathology
    Boone, L., Meyer, D., Cusick, P., Ennulat, D., Bolliger, A. P., Everds, N., Meador, V., Elliott, D., Honor, D., Bounous, D., & Jordan, H. (2005).
    Selection and Interpretation of Clinical Pathology Indicators of Hepatic Injury in Preclinical Studies. Veterinary Clinical Pathology, 34(3), 182-188. doi:10.1111/j.1939-165X.2005.tb00041.x

  • Long, G. (2004).
    Recommendations to Guide Determining Cause of Death in Toxicity Studies
    Toxicologic Pathology, 32(2):269-270. doi:10.1080/01926230490274443

  • Boorman, G., Dixon, D., Elwell, M., Kerlin, R., Morton, D., Peters, T., Regan, K., & Sullivan, J. (2004).
    Society of Toxicologic Pathology Position on Assessment of Hyperplastic
    Lesions in Rodent Carcinogenicity Studies. Toxicologic Pathology, 32:124-125, 2004. doi:10.1080/01926230490279402

  • Tuomari, D., Elliott, G., Kulwich, B., Yarrington, J., Fouillet, X., Geoly, F., & Long, P. (2004).
    Society of Toxicologic Pathology Position on Histopathology Data Collection and Audit Trail: Compliance with 21 CFR Parts 58 and 11. Toxicologic Pathology, 32(1), 122-123. doi:10.1080/01926230490268710

  • Crissman, J. W., Goodman, D. G., Hildebrandt, P. K., Maronpot, R. R., Prater, D. A., Riley, J. H., Seaman, W. J., & Thake, D. C. (2004).
    Best Practices Guideline: Toxicologic Histopathology. Toxicologic Pathology, 32(1), 126-131. doi:10.1080/01926230490268756

  • Bregman, C. L., Adler, R. R., Morton, D. G., Regan, K. S., & Yano, B. L. (2003).
    Recommended Tissue List for Histopathologic Examination in Repeat-Dose Toxicity and Carcinogenicity Studies: A Proposal of the Society of Toxicologic Pathology (STP). Toxicologic Pathology, 31(2), 252-253. doi:10.1080/01926230390183751

  • Lanning, L. L., Creasy, D. M., Chapin, R. E., Mann, P. C., Barlow, N. J., Regan, K. S., & Goodman, D. G. (2002).
    Recommended Approaches for the Evaluation of Testicular and Epididymal Toxicity. Toxicologic Pathology, 30(4), 507-520. doi:10.1080/01926230290105695

  • Morton, D., Elwell M., Tuomari, D. (2002).
    The Society of Toxicologic Pathology's Recommendations on Statistical Analysis of Rodent Carcinogenicity Studies
    Toxicologic Pathology, 30(3):415-418. doi:10.1080/01926230252930006

  • Morton, D. (2001).
    The Society of Toxicologic Pathology's Position on Statistical Methods for Rodent Carcinogenicity Studies. Toxicologic Pathology, 29(6), 670-672. doi:10.1080/019262301753386004

  • Nold, J. B., Keenan, K. P., Nyska, A., & Cartwright, M. E. (2001).
    Society of Toxicologic Pathology Position Paper: Diet as a Variable in Rodent Toxicology and Carcinogenicity Studies. Toxicologic Pathology, 29(5), 585-586. doi:10.1080/019262301317226393

  • PETO Analysis Working Group of STP. (2001).
    Draft Recommendations on Classification of Rodent Neoplasms for Peto Analysis. Toxicologic Pathology, 29(2), 265-268. doi:10.1080/019262301317052558

  • Levin S, Bucci TJ, Cohen SM, et al. (1997).
    The Nomenclature of Cell Death: Recommendations of an ad hoc Committee of the Society of Toxicologic Pathologists. Toxicologic Pathology, 27(4):484-490. doi:10.1177/019262339902700419

  • STP Regulatory Affairs Committee. (1997).
    Documentation of Pathology Peer Review. Toxicologic Pathology, 25(6), 655-655. doi:10.1177/019262339702500624

  • Levin, S. (1997).
    Commentary: Implementation of the STP Recommendations on the Nomenclature of Cell Death    . Toxicologic Pathology, 27(4):491. doi:10.1177/019262339902700420

  • Mohr, U. (1997).
    Commentary: Comments on the Cell Death Nomenclature Recommendations of the Society of Toxicologic Pathologists. Toxicologic Pathology, 27(4):497. doi:10.1177/019262339902700424
    •  11190 Sunrise Valley Drive,
      Suite 300, Reston, VA 20191
    To anonymously report suspected criminal activity or illegal or unethical conduct by an STP member, management staff, or participant in any STP activity or STP business relationship, call the Navex toll-free fraud hotline at 800-826-6762.
    Policies and Disclaimers
    Copyright © Society of Toxicologic Pathology, Inc. All rights reserved.